Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis: Biological Significance and Clinical Relevance. 13th Annual Offering – A Continuing Education Course

Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA

Further information from:
Ms C Lyons, Administrator, Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Tel: +1 617 726 4083 Fax: +1 617 726 4172

ESPOIO European Conference of Psychosocial Oncology
Stockholm, Sweden

Further information from:
ESPOIO Stockholm Convention Bureau, Box 6911, S-102 39 Stockholm, Sweden. Fax: +46 8 34 84 41 Email: ESPOIO@Stocon.se

5th International Conference on Long-term Complications of Treatment of Children and Adolescents for Cancer
Queen’s Landing at Niagara-on-the-Lake, Ontario, Canada

Further information from:
Daniel M Green, MD, Department of Pediatrics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Tel: (716) 845 2334; Fax: (716) 845 8003; Email: green@sc3101.med.buffalo.edu

Second Cuneo Lung Cancer Conference
Terme di Valdieri, Italy

Further information from:
Cuneo Lung Cancer Study Group (CuLCA SG), Via Romita, 15 12011 Borgo S Dalmazzo, Cuneo, Italy. Tel: 39171 260065

IXth Symposium Mammographicum
University of York, Heslington, York, UK

Further information from:
Symposium Mammographicum 98 Secretariat, Congress House, 65 West Drive, Cheam, Sutton, Surrey SM2 7NB, UK.
Tel: +44 (0) 181 661 0877; Fax: +44 (0) 181 661 9036

Erratum

Kinetics of mouse jejunal radiosensitization by 2’,2’-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells
V Grégoire, M Beauduin, J-F Rosier, B De Coster, M Bruiaux, M Octave-Prigot and P Scalliet

Br J Cancer 76: 1315–1321

Due to an error in film output figures 1 and 3 of this paper were incorrect when the paper was published. The publishers wish to apologise to the authors, editors and readers for this serious error. The correct figures are reproduced below.

Figure 1 Effect of dFdC (150 mg kg⁻¹) on the tolerance of mouse jejunal to single-dose irradiation. Mice were treated by irradiation alone (○), dFdC given 3 h before irradiation (●) or dFdC given 48 h before irradiation (▲). Three days and 14 h after irradiation, mice were killed, the jejenum was removed, fixed in Bouin, paraffin embedded and stained with trichrome. The number of regenerated crypts per circumference was counted in two different sections per mouse. Each point is the average of 6 or 7 mice. Dose–response curves were fitted by a least square regression analysis.

Figure 3 Pharmacodynamics of DNA synthesis inhibition (■) and kinetics of mitotic index (●) in jejunal crypt cells. Mice were given 150 mg kg⁻¹ dFdC and, at 0, 3, 5, 6, 12, 15, 18, 24, 36 and 48 h after drug administration, jejunum was harvested and fixed in 10% neutral-buffered formalin. S-phase cells were labelled with BrdUrd (60 mg kg⁻¹) 30 min before tissue harvest. Sections were processed for immunohistochemical detection of BrdUrd-labelled nuclei using a specific antibody for BrdUrd-containing DNA. Labelling and mitotic indices were determined in two transversal jejunal sections per animal. Each point is an average (± s.e.m.) of three mice.